Cadherin-17

Cadherin-17

Cadherin-17 Overview

Molecule Name
Cadherin-17
Synonyms
Cadherin-17,CDH17,HPT-1,LI-cadherin
Drug Development Progress
Drugs in Clinical Trials17
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Liver-intestine cadherin,HPT-1,Intestinal peptide-associated transporter HPT-1,LI-cadherin,HPT-1 Cadherin,Cadherin 17, LI Cadherin (Liver-Intestine),HPT1,Human Intestinal Peptide-Associated Transporter HPT-1,LI Cadherin,Cadherin,Cadherin 17,Human Peptide Transporter 1
Background
Cadherin-17, also known as liver-intestine (LI) Cadherin, belongs to the cadherin family of calcium-dependent cell adhesion molecules. In vivo studies showed CDH17 knockout resulted in apoptotic PC tumor death through activating caspase-3 activity. Taken together, CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways and CDH17 could be targeted to develop an anti-PC therapeutic approach.

Cadherin-17 Product List

Species
  • Human(21)
  • Mouse(4)
  • Cynomolgus(3)
  • Rat(1)
  • Rhesus macaque(1)
Tag
  • Fc Tag(12)
  • His Tag(11)
  • His Tag & Avi Tag(4)
  • Fc Tag & Avi Tag(2)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(30)
Conjugate
  • Unconjugated(23)
  • Biotin-labeled(6)
  • FITC Labeled(1)
Grade
  • RUO(30)
Low Endotoxin
  • Yes(1)
  • No(29)
You Have Viewed 1-10 Of 30 Results
  • 1
  • 2
  • 3

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

How can CDH17 proteins and CDH17-expressing cells support CDH17-targeted ADC research?

Recombinant CDH17 proteins can support biochemical assessment of antibody binding, specificity, and cross-species reactivity during CDH17-targeted ADC research. Cell-based binding assays are needed to determine whether an antibody recognizes full-length CDH17 in its cell-surface context. ACROBiosystems provides recombinant CDH17 proteins together with a HEK293/Human CDH17 stable cell line with confirmed surface expression for these complementary evaluations.

How can recombinant CDH17 proteins support antibody candidate characterization?

CDH17 extracellular-region proteins can be used in ELISA, SPR, or BLI assays to assess target binding and, where applicable, binding kinetics or affinity. Domain-specific fragments can further indicate which extracellular region contributes to antibody recognition. His-tagged, Fc-tagged, Avi-tagged, and biotinylated formats allow the protein to be adapted to different capture and detection configurations.

Which CDH17 species should be used for cross-reactivity studies?

Human CDH17 is used to characterize binding to the human target, while cynomolgus monkey, rhesus macaque, mouse, and rat proteins can be used to examine species cross-reactivity. When comparing binding across species, proteins with comparable domain coverage and tag formats should be selected where possible. This helps reduce assay differences caused by protein format rather than sequence variation.

How should I select among His-tagged, Fc-tagged, and biotinylated CDH17 proteins?

The appropriate format depends primarily on the immobilization and detection design of the assay. His-tagged proteins provide a relatively small affinity tag, Fc-tagged proteins support Fc-based capture but may affect protein presentation or apparent avidity, and biotinylated proteins enable streptavidin-based immobilization. Potential interference from the tag or capture reagent should also be considered when comparing antibody binding.

What is the difference between full-length extracellular CDH17 protein and CDH17 domain fragments?

A full-length extracellular construct presents the complete extracellular region of CDH17, whereas truncated constructs represent selected regions of the target. Fragments such as CDH17 (129–244), CDH17 (341–449), and CDH17 (450–566) can help determine whether antibody binding is associated with a particular extracellular region. These fragments support domain-level binding analysis but do not independently identify the precise antibody epitope.

What is CDH17, and why is its extracellular region used in target research?

CDH17, also known as LI-cadherin, is a cell-surface adhesion protein with an extracellular region containing multiple cadherin domains. Recombinant extracellular CDH17 proteins provide soluble target reagents for studying antibody binding outside the cellular context. ACROBiosystems offers complete extracellular-domain constructs and region-specific fragments for different target characterization needs.
Asset Licensing Opportunity

Antibody Project Trading Platform

Project NameProject StageMolecule TypeMolecule SourceDisease AreaIndication
CDH17 mAb - 01PCCMonoclonalHumanized MouseSolid TumorColorectal cancer,Gastric Cancer
Project Name
CDH17 mAb - 01
Project Stage
PCC
Molecule Type
Monoclonal
Molecule Source
Humanized Mouse
Disease Area
Solid Tumor
Indication
Colorectal cancer,Gastric Cancer
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
LM-350LM-350Phase 2 ClinicalLaNova Medicines Ltd
Gastrointestinal Neoplasms; Neoplasms; Solid tumours
Details
7MW-49117MW-4911Phase 2 ClinicalMabwell (Shanghai) Bioscience Co Ltd
Colorectal Neoplasms; Gastrointestinal Neoplasms; Solid tumours
Details
CM518D1CM518D1; CM-518-D-1Phase 2 ClinicalKeymed Biosciences Co Ltd
Solid tumours
Details
HS-20110HS20110; HS-20110Phase 2 ClinicalChangzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd
Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours
Details
AMT-676AMT-676Phase 2 ClinicalMultitude Therapeutics Inc
Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
CHM-2101CDH17-CAR T; CHM-2101; CHM2101; CHM-2101 CAR-T cellsPhase 2 ClinicalUniversity Of Pennsylvania
Colorectal Neoplasms; Gastrointestinal Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms
Details
MRG-007MRG-007; ARR-217Phase 2 ClinicalLepu Biopharma Co Ltd
Colorectal Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
BI-905711BI-905711Phase 1 ClinicalBoehringer Ingelheim International Gmbh
Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms
Details
CabotamigARB-202Phase 1 ClinicalArbele Corp
Biliary Tract Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Stomach Neoplasms
Details
HDM-2017HDM-2017; HDM2017Phase 1 ClinicalHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Colorectal Neoplasms; Solid tumours
Details
SIM-0609SIM-0609; SIM0609Phase 1 ClinicalShanghai Xianwei Pharmaceutical Technology Co Ltd
Gastrointestinal Neoplasms; Neoplasm Metastasis; Solid tumours
Details
UCLH-801UCLH-801Phase 1 ClinicalUTC Therapeutics Inc
Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Neoplasms; Stomach Neoplasms
Details
Anti-CDH17 CAR-T cells Therapy (Guangzhou Bio-Gene Technology)Phase 1 ClinicalGuangzhou Bio-Gene Technology Co Ltd
Solid tumours
Details
Anti-CDH17 CAR-T Cell therapy (UTC Therapeutics)Phase 1 ClinicalUTC Therapeutics Inc
Solid tumours
Details
YL-217YL217; YL-217Phase 1 ClinicalMediLink Therapeutics Co Ltd
Solid tumours
Details
TORL-3-600TORL-3-600Phase 1 ClinicalTorl Biotherapeutics LLC
Colorectal Neoplasms; Solid tumours
Details
CDH17 - IHC Test(Arbele)ClinicalArbele Corp
Gastrointestinal Neoplasms
Details
Customer Reviews